Compare iShares Global Tech ETF (IXN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Global Tech ETF trades at $149.94 (market cap $10.03B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.7× iShares Global Tech ETF's market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IXN | VRTX | |
|---|---|---|
Market Cap | $10.03B | $127.55B |
Volume | 286,617 | 1,487,944 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $557.96 |
52-Week Low | $95.76 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $152.16, down 0.51% today but near its 52-week high of $151.40, reflecting strong momentum. Technical indicators show a bullish moving average signal but overbought RSI levels. Recent news highlights the ETF's 34% gain and multiple compression, with a high-teens P/E ratio and 28.5% long-term EPS growth rate, emphasizing global tech exposure beyond the U.S.
The outlook remains positive due to AI exposure and global diversification, but risks include portfolio concentration and overbought conditions. Analyst sentiment is bullish, with buy ratings citing valuation appeal, though investors should monitor tech sector volatility and competitive pressures from international firms.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
